Matt Winton

Matthew Winton, Ph.D., joined Inozyme as Senior Vice President and Chief Operating Officer in April 2023. Dr. Winton most recently served as senior vice president and head of the Multiple Sclerosis franchise for Biogen’s US organization. Previously, he was the head of Spinal Muscular Atrophy (SMA) franchise in the US, where he was responsible for setting strategic direction for the infant, pediatric, and adult markets. Dr. Winton also served as Director, Payer and Channel Marketing, where he was responsible for the development and execution of pricing, access, and reimbursement strategies across various therapeutic franchises. In particular, he helped successfully prepare the organization for the approval and launch its first orphan disease drug, SPINRAZA.